Does RISANKIZUMAB-RZAA Cause Central venous catheterisation? 31 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 31 reports of Central venous catheterisation have been filed in association with RISANKIZUMAB-RZAA. This represents 0.1% of all adverse event reports for RISANKIZUMAB-RZAA.
31
Reports of Central venous catheterisation with RISANKIZUMAB-RZAA
0.1%
of all RISANKIZUMAB-RZAA reports
1
Deaths
17
Hospitalizations
How Dangerous Is Central venous catheterisation From RISANKIZUMAB-RZAA?
Of the 31 reports, 1 (3.2%) resulted in death, 17 (54.8%) required hospitalization.
Is Central venous catheterisation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 31 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Central venous catheterisation?
EPOPROSTENOL (361)
AMBRISENTAN (263)
TREPROSTINIL (208)
ECULIZUMAB (105)
VENETOCLAX (89)
MACITENTAN (78)
PEMBROLIZUMAB (70)
AZTREONAM LYSINE (63)
ADALIMUMAB (59)
NATALIZUMAB (57)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Central venous catheterisation Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA